GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004390316 | Endometrium | EEC | regulation of biological process involved in symbiotic interaction | 19/2168 | 72/18723 | 4.11e-04 | 4.35e-03 | 19 |
GO:005237215 | Endometrium | EEC | modulation by symbiont of entry into host | 14/2168 | 49/18723 | 9.88e-04 | 8.76e-03 | 14 |
GO:004852514 | Endometrium | EEC | negative regulation of viral process | 21/2168 | 92/18723 | 1.64e-03 | 1.29e-02 | 21 |
GO:004659613 | Endometrium | EEC | regulation of viral entry into host cell | 12/2168 | 42/18723 | 2.23e-03 | 1.66e-02 | 12 |
GO:004507112 | Endometrium | EEC | negative regulation of viral genome replication | 14/2168 | 56/18723 | 3.91e-03 | 2.60e-02 | 14 |
GO:190390112 | Endometrium | EEC | negative regulation of viral life cycle | 8/2168 | 25/18723 | 5.62e-03 | 3.38e-02 | 8 |
GO:00354564 | Endometrium | EEC | response to interferon-beta | 9/2168 | 32/18723 | 8.63e-03 | 4.70e-02 | 9 |
GO:0016032111 | Esophagus | ESCC | viral process | 301/8552 | 415/18723 | 3.34e-29 | 1.32e-26 | 301 |
GO:0019058111 | Esophagus | ESCC | viral life cycle | 226/8552 | 317/18723 | 1.17e-20 | 1.76e-18 | 226 |
GO:0019079111 | Esophagus | ESCC | viral genome replication | 102/8552 | 131/18723 | 4.31e-14 | 2.19e-12 | 102 |
GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
GO:0050792111 | Esophagus | ESCC | regulation of viral process | 119/8552 | 164/18723 | 2.19e-12 | 9.03e-11 | 119 |
GO:1903900111 | Esophagus | ESCC | regulation of viral life cycle | 106/8552 | 148/18723 | 1.26e-10 | 3.72e-09 | 106 |
GO:0044403111 | Esophagus | ESCC | biological process involved in symbiotic interaction | 186/8552 | 290/18723 | 1.43e-10 | 4.16e-09 | 186 |
GO:0045069110 | Esophagus | ESCC | regulation of viral genome replication | 67/8552 | 85/18723 | 3.81e-10 | 1.04e-08 | 67 |
GO:00516075 | Esophagus | ESCC | defense response to virus | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
GO:01405465 | Esophagus | ESCC | defense response to symbiont | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
GO:0051701111 | Esophagus | ESCC | biological process involved in interaction with host | 135/8552 | 203/18723 | 1.49e-09 | 3.49e-08 | 135 |
GO:003434013 | Esophagus | ESCC | response to type I interferon | 48/8552 | 58/18723 | 6.18e-09 | 1.26e-07 | 48 |
GO:0052126111 | Esophagus | ESCC | movement in host environment | 117/8552 | 175/18723 | 1.14e-08 | 2.26e-07 | 117 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FITM2 | SNV | Missense_Mutation | | c.645N>A | p.Asn215Lys | p.N215K | Q8N6M3 | protein_coding | deleterious(0) | benign(0.089) | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
FITM2 | insertion | Frame_Shift_Ins | novel | c.72_73insGCGAACCTCGTCTCTTCTAAAA | p.Pro25AlafsTer134 | p.P25Afs*134 | Q8N6M3 | protein_coding | | | TCGA-AN-A0FK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
FITM2 | insertion | Frame_Shift_Ins | novel | c.70_71insAGCCTGTCCAACA | p.Leu24GlnfsTer132 | p.L24Qfs*132 | Q8N6M3 | protein_coding | | | TCGA-AN-A0FK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
FITM2 | SNV | Missense_Mutation | rs370245406 | c.487N>A | p.Ala163Thr | p.A163T | Q8N6M3 | protein_coding | tolerated(0.26) | benign(0.04) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
FITM2 | SNV | Missense_Mutation | rs771219892 | c.253N>A | p.Gly85Ser | p.G85S | Q8N6M3 | protein_coding | tolerated(0.43) | possibly_damaging(0.593) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
FITM2 | SNV | Missense_Mutation | novel | c.118N>A | p.Glu40Lys | p.E40K | Q8N6M3 | protein_coding | deleterious(0.02) | possibly_damaging(0.631) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FITM2 | SNV | Missense_Mutation | novel | c.581N>T | p.Ala194Val | p.A194V | Q8N6M3 | protein_coding | deleterious(0) | possibly_damaging(0.611) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
FITM2 | SNV | Missense_Mutation | novel | c.152N>G | p.Asn51Ser | p.N51S | Q8N6M3 | protein_coding | tolerated(0.42) | benign(0.112) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
FITM2 | SNV | Missense_Mutation | rs755374181 | c.539N>A | p.Arg180Gln | p.R180Q | Q8N6M3 | protein_coding | tolerated(0.4) | possibly_damaging(0.849) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
FITM2 | SNV | Missense_Mutation | novel | c.499G>A | p.Val167Ile | p.V167I | Q8N6M3 | protein_coding | tolerated(0.19) | benign(0.038) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |